EMA Backs Cosentyx for Adolescent Hidradenitis Suppurativa

European regulators recommend the psoriasis and arthritis drug for patients aged 12 and older with moderate to severe HS.

Updated on Nov. 16, 2026 in Allergies

EMA Backs Cosentyx for Adolescent Hidradenitis Suppurativa

The European Medicines Agency's CHMP has adopted a positive opinion recommending marketing authorization of Novartis's Cosentyx for adolescents aged 12 and older with moderate to severe hidradenitis suppurativa. The recommendation applies to patients who have had an inadequate response to conventional systemic HS therapy.

Why it matters

Hidradenitis suppurativa often begins during adolescence, when the disease can progress to irreversible scarring and treatment options for this age group are limited. A European authorization would make Cosentyx the only IL-17A inhibitor approved for adolescent HS in Europe.

The CHMP opinion is a regulatory committee recommendation, not a final approval, with exposure in adolescents inferred from adult HS trials, psoriasis pharmacokinetic modelling and weight-based dosing analyses. The European Commission's final decision, expected in about two months, remains unresolved.

The players

Novartis

Novartis is a Swiss multinational pharmaceutical company that develops and markets Cosentyx, an interleukin-17A inhibitor used across several immune-mediated conditions.

European Medicines Agency

The European Medicines Agency is the European Union body responsible for the scientific evaluation and supervision of medicines, and its CHMP committee issues authorization recommendations.

The details

The opinion rests on efficacy and safety data from adult HS studies, pharmacokinetic modelling extrapolated from adult HS and psoriasis trials, pediatric data from other approved Cosentyx indications, and weight-based dosing analyses. Cosentyx is a fully human biologic that directly inhibits interleukin-17A.

Timeline

  1. November 16, 2026: CHMP adopts positive opinion, announced by Novartis.

  2. Approximately two months later: European Commission expected to issue final decision.

Health Landscape

The European recommendation follows the US pediatric approval of Cosentyx for moderate to severe HS in patients aged 12 and older, extending that adolescent indication to Europe. It also reflects a broader push to bring IL-17A inhibitors into HS care, a disease in which more than 50% of cases begin during puberty.

For adolescents with moderate to severe hidradenitis suppurativa who have not responded to conventional therapy, an EU authorization would open a new treatment option. Families and clinicians in Europe would gain a biologic with dosing adjusted by body weight for this age group.

The takeaway

Adolescent-onset hidradenitis suppurativa is a chronic condition where earlier treatment may limit long-term scarring. Patients and parents should discuss emerging biologic options with a dermatologist if standard therapy has not controlled symptoms.

What happens next

The European Commission is expected to issue its final decision on the Cosentyx recommendation in approximately two months.

Further reading

For more on the immune-driven skin conditions behind this decision, explore our Allergies coverage.